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Abstract
Background: HIV/AIDS pandemic is a worldwide public health issue. There is a need for new approaches to
develop new antiviral compounds or other therapeutic strategies to limit viral transmission. The envelope
glycoproteins gp120 and gp41 of HIV are the main targets for both silver nanoparticles (AgNPs) and neutralizing
antibodies. There is an urgency to optimize the efficiency of the neutralizing antibodies (NABs). In this study, we
demonstrated that there is an additive effect between the four NABs and AgNPs when combined against cell-
associated HIV-1 infection in vitro
Results: Four NABs (Monoclonal antibody to HIV-1 gp41 126-7, HIV-1 gp120 Antiserum PB1 Sub 2, HIV-1 gp120
Antiserum PB1, HIV-1 gp120 Monoclonal Antibody F425 B4e8) with or without AgNPs of 30-50 nm in size were tested
against cell free and cell-associated HIVIIIB virus. All NABs inhibited HIV-1 cell free infection at a dose response manner,
but with AgNPs an antiviral additive effect was not achieved Although there was no inhibition of infection with cell-
associated virus by the NABs itself, AgNPs alone were able to inhibit cell associated virus infection and more
importantly, when mixed together with NABs they inhibited the HIV-1 cell associated infection in an additive manner.
Discussion: The most attractive strategies to deal with the HIV problem are the development of a prophylactic
vaccine and the development of effective topical vaginal microbicide. For two decades a potent vaccine that
inhibits transmission of infection of HIV has been searched. There are vaccines that elicit NABs but none of them
has the efficacy to stop transmission of HIV-1 infection. We propose that with the addition of AgNPs, NABs will
have an additive effect and become more potent to inhibit cell-associated HIV-1 transmission/infection.
Conclusions: The addition of AgNPs to NABs has significantly increased the neutralizing potency of NABs in
prevention of cell-associated HIV-1 transmission/infection. Further exploration is required to standardize
potentiation of NABs by AgNPs. It is also required to evaluate in vivo toxicity of AgNPs before AgNPs could be
incorporated in any antiviral vaginal creams.
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Introduction
The pandemic of Acquired Immunodeficiency Syndrome
(AIDS), caused by the Human Immunodeficiency Virus
Type 1 (HIV-1) infection, is a worldwide public health
issue [1]. The latest estimates by the Joint United
Nations Program on HIV/AIDS (UNAIDS) indicate that
more than 33.3 million people worldwide are living with
HIV-1 infection or AIDS.
The medical use of the cocktail drugs known as highly
active antiretroviral therapies (HAART) has significantly
reduced morbidity and mortality among AIDS patients
[2,3]. Unfortunately, the achievement of HAART is
insufficient and compromised by the evolution of drug
resistance HIV strains [4]. Consequently, the search for
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new therapies to inhibit viral infection or to restore the
damaged immune system in HIV/AIDS patients con-
tinues. Newly discovered drugs are constantly evaluated
as therapeutic drug candidates. These new drugs are
eagerly awaited for the growing number of HIV-infected
individuals who have developed resistance to the cur-
rently existing antiretrovirals [5].
The most attractive strategies to deal with the HIV
problem are the development of a prophylactic vaccine
and the development of an effective topical vaginal and
rectal microbicides. Both approaches are essential and
eventually a combination of the two may prove to be
most effective strategy in controlling the HIV-1 epi-
demic by diminishing the incidence of human-to-human
transmission events [6].
The discovery of an HIV-1 vaccine that elicits broadly
efficient neutralizing antibodies still remains an elusive
goal especially after the recent failure of the leading T
cell based HIV vaccine in human efficacy trials [7]. The
envelope glycoproteins gp120 and gp41 that are the
main targets for neutralizing antibodies are partially
shielded by N-linkedglycans and other structurally-
imposed steric constraints that limit antibody access to
potential neutralization epitopes. The complex level of
antigenic diversity of HIV-1, the shielding of key epi-
topes within the three dimensional structure of the
native Env trimer, and the failure of newer versions of
Env proteins to elicit broadly reactive antibodies have
led to some pessimism regarding the potential to ever
elicit high titers of neutralizing antibodies against
diverse strains of HIV-1. Therefore there is a need to
maximize the efficiency of whatever titers of neutralizing
antibodies generated by vaccines [8].
A significant correlation is usually reported linking the
ability of an antibody to neutralize HIV-1 in vitro and
to protect in vivo against HIV-1 in animal models.
Some vaccine research studies have measured the cap-
ability of specific NABs to protect against SHIV infec-
tion, and found that efficient immunity is achieved only
when the serum concentration of NABs in the chal-
lenged animals is many multiples of the in vitro neutra-
lization titer. Normally these NABs require relatively
high antibody concentrations that may be highly difficult
to reach by vaccination [9].
Silver ions in complexes or compounds have been
used for centuries to disinfect fluids, solids and tissues
[10]. There is no cross resistance with antibiotics [11]
and probably there is also no induction of antimicrobial
resistance by silver ions [12]. The Crede’s solution (sil-
ver nitrate 0.2%) has been used to prevent the Neonatal
conjunctivitis ("ophtalmia neonatorum”) which is a form
of bacterial conjunctivitis contracted during delivery.
The eyes are infected during passage through the birth
canal from a mother infected with either Neisseria
gonorrhoeae or Chlamydia trachomatis. Crede’s solution
was used to prevent the condition. If left untreated it
could cause blindness [13]. Also Silver sulfadiazine is
widely used by physicians to treat severe burns in skin,
this topical cream not only acts against infections, but
also against inflammation and enhance the healing of
the tissue. The many attempts to find a better remedy
for the topical treatment of burns than silver sulphadia-
zine have so far been without success [14].
Recent advances in nanotechnology have enabled the
scientific community to investigate and manipulate
materials at nanometer level. Nano-based delivery sys-
tems can be adapted to modulate drug release, reduce
drug-associated toxicity, protect drugs from metabolism,
and target drugs to affected cells, tissues, and compart-
ments [15-19]. Nowadays we can use pure silver of nan-
ometer sizes. We previously reported that AgNPs inhibit
HIV-1 and that these nanoparticles attach to the gp120
[20]. Then we investigated the mode of antiviral action,
with a panel of tests we probed that AgNPs:- a) attach
to the envelope of the HIV-1 inhibiting the interaction
with CD4 receptor,:-b) inhibits a wide range of HIV-1
regardless of the tropism,:-c) inhibit entry and fusion of
the virus to the target cell at a non-toxic range. AgNPs
proved to be more efficient than silver ions at non-cyto-
toxic levels [21].
With the above antiviral characteristics, AgNPs are
appealing to be included as an active compound in a
vaginal topical gel. We previously demonstrated that
Polyvinylpyrrolidone (PVP) AgNPs mixed in a topical
gel, inhibit the transmission of infection when applied to
the human cervical tissue in a model for explants, at a
non-toxic range, and more significantly, AgNPs acts
rapidly in less than a minute and protect the human
cervical tissue for more than 48 hours even after an
extensive wash of the gel, without any toxicity to the
human cervical explants [22].
In the present study we decided to investigate the
additive effect of AgNPs with four NABs (Monoclonal
antibody to HIV-1 gp41 126-7 [23], HIV-1 gp120 Anti-
serum PB1 Sub 2, HIV-1 gp120 Antiserum PB1 [24-26],
HIV-1 gp120 Monoclonal Antibody F425 B4e8 [27]) as
both act against viral envelope glycoprotein trimers on
the surface of the virus that mediate receptor binding
and entry.
Results
Inhibition of cell free HIVIIIB virus infection by Monoclonal
antibody to HIV-1 gp41 (126-7) and Silver Nanoparticles
in U373-MAGI-CXCR4CEM cells
In this experiment, we evaluated inhibition of cell free
HIV-1IIIB virus infection by monoclonal antibody to
HIV-1 gp41 (126-7) in U373-MAGI-CXCR4CEM cells.
The toxic dose of 1 mg/ml AgNPs was ascertained on a
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cytotoxicity assay and was found to be 28% (data not
shown). The AgNPs alone showed 40% inhibition of cell
free HIV-1IIIB virus infection at this concentration
against a control (virus infection wihout AgNPs). The
monoclonal antibody to HIV-1 gp41 (126-7) alone
showed ability to inhibit infection (16-25%) of HIV-1IIIB
in a dose response manner. The different dilutions of
NAB, when added with AgNPs at 1 mg/mL, increased
HIV-1IIIB inhibition by 47-63% (P < 0.002) until the
NAB dilution of 1:160. There was no additive effect
observed.(Figure 1).
Inhibition of cell free HIVIIIB virus infection by HIV-1
gp120 Antiserum (PB1) and Silver Nanoparticles in U373-
MAGI-CXCR4CEM cells
The HIV-1 gp120 Antiserum (PB1) alone showed inhibi-
tion of HIV-1 IIIB infection in a dose response manner
(10-30%). The addition of AgNPs at 1 mg/mL showed
no effect in this experiment. The HIV-1 gp120 Anti-
serum (PB1) dilutions 1:20 and 1:40 showed mild inhibi-
tion alone when compared to the inhibition by the
mixture of AgNPs and NABs (47 and 41% inhibition, P
< 0.065). After that dilution inhibition of HIV-1 IIIB
virus decreased and was less than AgNPs alone 40%,
(Figure 2).
Inhibition of cell free HIVIIIB virus infection by HIV-1
gp120 Antiserum (PB1 Sub 2) and Silver Nanoparticles in
U373-MAGI-CXCR4CEM cells
The HIV-1 gp120 Antiserum (PB1 sub 2) alone was
found to have the best ability to inhibit infection of
HIV-1IIIB (18-71%) in a dose response manner com-
pared to other three NABs. When added with AgNPs at
1 mg/mL, an increase of inhibitory effect was observed
until the NAB dilution of 1:640. The addition of AgNPs
Figure 1 HIV inhibition of cell free HIVIIIB virus infection by
Monoclonal antibody to HIV-1 gp41 (126-7) and Silver
Nanoparticles. Serial two-fold dilutions of Monoclonal antibody to
HIV-1 gp41 (126-7) were added to 105 TCID50 of HIV-1IIIB cell-free
virus. After incubation for 5 minutes, they were added with or
without silver nanoparticles at 1 mg/mL. Then the mixture was
placed into 96-well plates with indicator cells (U373-MAGI-
CXCR4CEM) at a final 0.2-0.5 m.o.i. Assessment of HIV-1 infection was
made with a luciferase-based assay. The percentage of residual
infectivity after treatment was calculated with respect to the
positive control of untreated virus. The assay was performed in
triplicate; the data points represent the mean, and the solid lines
are nonlinear regression curves done with SigmaPlot 10.0 software.
By means of Mann- Whitney Rank Sum test we compared the
difference in the median values between the two groups (only
AgNPs and AgNPs with antibody to HIV-1 gp41 126-7) is greater
than would be expected by chance; there is a statistically significant
difference (P < 0.002).
Figure 2 HIV inhibition of cell free HIVIIIB virus infection by
HIV-1 gp120 Antiserum (PB1) and Silver Nanoparticles. Serial
two-fold dilutions of HIV-1 gp120 Antiserum (PB1) was added to 105
TCID50 of HIV-1IIIB cell-free virus. After incubation for 5 minutes, they
were added with or without silver nanoparticles at 1 mg/mL. Then
the mixture was placed into 96-well plates with indicator cells
(U373-MAGI-CXCR4CEM) at a final 0.2-0.5 m.o.i. Assessment of HIV-1
infection was made with a luciferase-based assay. The percentage of
residual infectivity after treatment was calculated with respect to
the positive control of untreated virus. The assay was performed in
triplicate; the data points represent the mean, and the solid lines
are nonlinear regression curves done with SigmaPlot 10.0 software.
By means of Mann- Whitney Rank Sum test we compared the
difference in the median values between the two groups (only
AgNPs and AgNPs with antibody to HIV-1 gp120 Antiserum PB1) is
not great enough to exclude the possibility that the difference is
due to random sampling variability; there is not a statistically
significant difference (P < 0.065).
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increased HIV-1IIIB inhibition (42-72%, P < 0.008). there
was no additive effect. (Figure 3).
Inhibition of cell free HIVIIIB virus infection by HIV-1
gp120 Monoclonal Antibody (F425 B4e8) and Silver
Nanoparticles in U373-MAGI-CXCR4CEM cells
The HIV-1 gp120 Monoclonal Antibody (F425 B4e8)
was found to mildly inhibit infection of HIV-1IIIB in a
dose response manner (5-11%). When added with
AgNPs at 1 mg/mL no effect was observed. The use of
AgNPs along with HIV-1 gp120 Monoclonal Antibody
(F425 B4e8) showed inhibition efficacy of NAB 36-40%
(P < 0.008) which was less than AgNPs alone (Figure 4).
Inhibition of cell associated HIVIIIB/H9 virus infection by
Monoclonal antibody to HIV-1 gp41 (126-7), and Silver
Nanoparticles in U373-MAGI-CXCR4CEM cells
The monoclonal antibody to HIV-1 gp41 (126-7) itself
has very little effect (6-10% inhibition) on cell associated
HIV-1IIIB/H9 virus infection. The AgNPs however
showed inhibition of HIV-1IIIB/H9 virus infection (50%)
at 1 mg/mL concentration. The monoclonal antibody to
HIV-1 gp41 (126-7) when added with AgNPs showed
additive effect till 1:640 dilutions, increasing inhibition
of HIV-1IIIB/H9 virus to 62-71% (P < 0.002). This inhibi-
tory effect was however lost after 1:640 dilution of NAB
and only the inhibition of AgNPs alone were observed
(Figure 5).
Inhibition of cell associated HIVIIIB/H9 virus infection by
HIV-1 gp120 Antiserum (PB1) and Silver Nanoparticles in
U373-MAGI-CXCR4CEM cells
The HIV-1 gp120 Antiserum (PB1) showed 3-12% inhibi-
tory effect on cell associated HIV-1IIIB/H9 virus, addition of
AgNPs at 1 mg/mL increased inhibition of virus (60-68%
inhibition, P < 0.002) suggesting a strong additive effect of
AgNPs on HIV-1 gp120 Antiserum-PB1(Figure 6).
Figure 3 HIV inhibition of cell free HIVIIIB virus infection by
HIV-1 gp120 Antiserum (PB1 Sub 2) and Silver Nanoparticles.
Serial two-fold dilutions of HIV-1 gp120 Antiserum (PB1 Sub 2) was
added to 105 TCID50 of HIV-1IIIB cell-free virus. After incubation for 5
minutes, were added with or without silver nanoparticles at 1 mg/
mL. Then the mixture was placed into 96-well plates with indicator
cells (U373-MAGI-CXCR4CEM) at a final 0.2-0.5 m.o.i. Assessment of
HIV-1 infection was made with a luciferase-based assay. The
percentage of residual infectivity after treatment was calculated with
respect to the positive control of untreated virus. The assay was
performed in triplicate; the data points represent the mean, and the
solid lines are nonlinear regression curves done with SigmaPlot 10.0
software. By means of Mann- Whitney Rank Sum test we compared
the difference in the median values between the two groups (only
AgNPs and AgNPs with antibody to HIV-1 gp120 Antiserum PB1
Sub 2) is greater than would be expected by chance; there is a
statistically significant difference (P < 0.008).
Figure 4 HIV inhibition of cell free HIVIIIB virus infection by
HIV-1 gp120 Monoclonal Antibody (F425 B4e8) and Silver
Nanoparticles. Serial two-fold dilutions of HIV-1 gp120 Monoclonal
Antibody (F425 B4e8) was added to 105 TCID50 of HIV-1IIIB cell-free
virus. After incubation for 5 minutes, they were added with or
without silver nanoparticles at 1 mg/mL. Then the mixture was
placed into 96-well plates with indicator cells (U373-MAGI-
CXCR4CEM) at a final0.2-0.5 m.o.i. Assessment of HIV-1 infection was
made with a luciferase-based assay. The percentage of residual
infectivity after treatment was calculated with respect to the
positive control of untreated virus. The assay was performed in
triplicate; the data points represent the mean, and the solid lines
are nonlinear regression curves done with SigmaPlot 10.0 software.
By means of Mann- Whitney Rank Sum test we compared the
difference in the median values between the two groups (only
AgNPs and AgNPs with antibody to HIV-1 gp120 Monoclonal
Antibody F425 B4e8) is greater than would be expected by chance;
there is a statistically significant difference (P < 0.008).
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Inhibition of cell associated HIVIIIB/H9 virus infection by
HIV-1 gp120 Antiserum (PB1 Sub 2) and Silver
Nanoparticles in U373-MAGI-CXCR4CEM cells
The HIV-1 gp120 Antiserum (PB1 sub 2) alone showed
3-12% inhibition of cell associated HIV-1IIIB/H9 virus
infection in a dose response manner. This inhibition
was increased to 61-69% inhibition (P < 0.002) when
added with AgNPs at 1 mg/mL concentration indicating
an additive effect between AgNPs and HIV-1 gp120
Antiserum-PB1 Sub 2 (Figure 7).
Inhibition of cell associated HIVIIIB/H9 virus infection by
HIV-1 gp120 Monoclonal Antibody (F425 B4e8) and Silver
Nanoparticles in U373-MAGI-CXCR4CEM cells
The HIV-1 gp120 Monoclonal Antibody (F425 B4e8)
alone showed 1-9% inhibition of cell associated HIV-
1IIIB/H9 virus infection in a dose response manner. Addi-
tion of AgNPs at 1 mg/mL concentration resulted in
significant increase (P < 0.002) in the inhibitory effect of
this cocktail signifying an additive effect between AgNPs
and HIV-1 gp120 Monoclonal Antibody (F425 B4e8).
The inhibition of cell associated HIV-1IIIB/H9 virus infec-
tion increased to 58-60% (Figure 8).
Discussion
Vaccine-induced neutralizing antibodies that inhibit viral
entry or fusion to the target cell are the protective cor-
relates of most existing HIV vaccines [[8,9] and [23]].
Nevertheless, for highly variable viruses such as HIV-1,
the ability to elicit broadly neutralizing antibody
responses through vaccination has proven to be extre-
mely difficult.
The major targets for HIV-1 NABs are the viral envel-
ope glycoprotein trimers on the surface of the virus that
mediate receptor binding and entry [24,27]. HIV-1 has
evolved many mechanisms on the surface of envelope
glyco-proteins to evade antibody-mediated neutraliza-
tion, including the masking of conserved regions by gly-
can, quaternary protein interactions and the presence of
immunodominant variable elements. In our previous
Figure 5 HIV inhibition of cell associated HIVIIIB virus infection
by Monoclonal antibody to HIV-1 gp41 (126-7) and Silver
Nanoparticles. Chronically HIV-1-infected H9 (105 cells) were
incubated with serial two-fold dilutions of HIV-1 gp120 Antiserum
(PB1) for 5 minutes with or without silver nanoparticles at 1 mg/mL.
Then treated H9 cells were placed into 96-well plates with indicator
cells (U373-MAGI-CXCR4CEM). Assessment of HIV-1 infection was
made with a luciferase-based assay after 48 hours. The assay was
performed in triplicate; the data points represent the mean, and the
solid lines are nonlinear regression curves done with SigmaPlot 10.0
software. By means of Mann- Whitney Rank Sum test we compared
the difference in the median values between the two groups (only
AgNPs and AgNPs with antibody to HIV-1 gp41 126-7) is greater
than would be expected by chance; there is a statistically significant
difference (P < 0.002).
Figure 6 HIV inhibition of cell associated HIVIIIB virus infection
by HIV-1 gp120 Antiserum (PB1) and Silver Nanoparticles.
Chronically HIV-1-infected H9 (105 cells) were incubated with serial
two-fold dilutions of Monoclonal antibody to HIV-1 gp41 (126-7) for
5 minutes with or without silver nanoparticles at 1 mg/mL. Then
treated H9 cells were placed into 96-well plates with indicator cells
(U373-MAGI-CXCR4CEM). Assessment of HIV-1 infection was made
with a luciferase-based assay after 48 hours. The assay was
performed in triplicate; the data points represent the mean, and the
solid lines are nonlinear regression curves done with SigmaPlot 10.0
software. By means of Mann- Whitney Rank Sum test we compared
the difference in the median values between the two groups (only
AgNPs and AgNPs with antibody to HIV-1 gp120 Antiserum PB1) is
greater than would be expected by chance; there is a statistically
significant difference (P < 0.002).
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studies we have demonstrated that silver nanoparticles
also bind to gp120 and gp41 part of HIV-1 envelop to
inhibit HIV-1 infectivity [21,22].
The silver nanoparticles and NABs both use epitopes
on the HIV-1 envelope glycoproteins as their binding
targets. It was important to study if they could increase
HIV-1 inhibition when used together. In our previous
studies, we had reported toxicity and dose dependent
inhibition of HIV-1IIIB by silver nanoparticles [21,22]. In
the present study, we have used most effective but least
toxic concentration of silver nanoparticles [21] to evalu-
ate its effect on neutralizing ability of four NABs against
cell free HIV-1IIIB and cell associated HIV-1IIIB/H9 virus
in U373-MAGI-CXCR4CEM cells. In the first experi-
ment, we evaluated inhibition of cell free HIV-1IIIB virus
infection by monoclonal antibody to HIV-1 gp41 (126-
7), HIV-1 gp120 antiserum (PB1), HIV-1 gp120 anti-
serum (PB1 sub 2), HIV-1 gp120 monoclonal antibody
(F425B4e8), and compared that with HIV-1 inhibition
by AgNPs alone and relevant NABs + AgNPs cocktail.
Out of four NABs used, the HIV-1 gp120 antiserum
(PB1 sub 2) was most potent NAB (neutralizing
antibody) in inhibition of HIV-1IIIB. It was expected as
this antibody has been raised against HIV-1IIIB virus.
Other three heterologous NABs were found to have
varying degrees of HIV-1IIIB inhibitory potencies. AgNPs
at 1 mg/ml concentration have been shown to exert
~40% inhibition of cell free HIV-1IIIB virus infection.
When NABs and AgNPs were used together, we
recorded no additive effect of inhibition of cell free
HIV-1IIIB Virus infection.
Inhibition of cell -associated virus infection has been
found difficult to achieve by the NABs alone. A few
NABs when used at high titers were able to inhibit cell
associated homologous virus. We attempted to record if
AgNPs will be able to increase inhibition of cell asso-
ciated virus by homologous and heterologous NABs.
Since cell free and cell associated both viruses are pre-
sent in the infectious inoculums in real life, any increase
in inhibitory potencies of NABs against HIV-1IIIB/H9
virus infection will be interesting. In our experiments,
we have used all four NABs, described earlier, to
Figure 7 HIV inhibition of cell associated HIVIIIB virus infection
by HIV-1 gp120 Antiserum (PB1 Sub 2) and Silver
Nanoparticles. Chronically HIV-1-infected H9 (105 cells) were
incubated with serial two-fold dilutions of Monoclonal antibody to
HIV-1 gp120 Antiserum (PB1 Sub 2) for 5 minutes with or without
silver nanoparticles at 1 mg/mL. Then treated H9 cells were placed
into 96-well plates with indicator cells (U373-MAGI-CXCR4CEM).
Assessment of HIV-1 infection was made with a luciferase-based
assay after 48 hours. The assay was performed in triplicate; the data
points represent the mean, and the solid lines are nonlinear
regression curves done with SigmaPlot 10.0 software. By means of
of Mann- Whitney Rank Sum test we compared the difference in
the median values between the two groups (only AgNPs and
AgNPs with antibody to HIV-1 gp120 Antiserum PB1 Sub 2) is
greater than would be expected by chance; there is a statistically
significant difference (P < 0.002).
Figure 8 HIV inhibition of cell associated HIVIIIB virus infection
by HIV-1 gp120 Monoclonal Antibody (F425 B4e8) and Silver
Nanoparticles. Chronically HIV-1-infected H9 (105 cells) were
incubated with serial two-fold dilutions of HIV-1 gp120 Monoclonal
Antibody (F425 B4e8) for 5 minutes with or without silver
nanoparticles at 1 mg/mL. Then treated H9 cells were placed into
96-well plates with indicator cells (U373-MAGI-CXCR4CEM).
Assessment of HIV-1 infection was made with a luciferase-based
assay after 48 hours. The assay was performed in triplicate; the data
points represent the mean, and the solid lines are nonlinear
regression curves done with SigmaPlot 10.0 software. By means of
Mann- Whitney Rank Sum test we compared the difference in the
median values between the two groups (only AgNPs and AgNPs
with antibody to HIV-1 gp120 Monoclonal Antibody F425 B4e8) is
greater than would be expected by chance; there is a statistically
significant difference (P < 0.002).
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evaluate their inhibitory effect on HIV-1IIIB/H9 virus
infection along with AgNPs. The NABs used in this set
of experiments alone did not show significant inhibition
(2-10% inhibition) of cell- associated virus HIV-1IIIB/H9
in U373-MAGI-CXCR4CEM cells. The AgNPs alone
however were successful in inhibiting cell associated
HIV-1IIIB/H9 virus infection. In fact AgNPs alone were
more potent (50% inhibition) with cell associated HIV-
1IIIB/H9 virus infection than cell free HIV-1IIIB virus
infection (40% inhibition). At present we do not know
the exact reason behind increased inhibition of cell asso-
ciated virus v/s cell free virus. We assume it may be due
to better binding between cell associated virus and
AgNPs. The use of AgNPs+ all four NABs cocktail,
however, produced significant increase in inhibition of
cell associated HIV-1IIIB/H9 virus infection. The use of
this cocktail resulted in 60 to 71% inhibition of cell
associated virus infection. All four antibodies used in
this experiment had almost similar increase in inhibition
of HIV-1IIIB/H9 virus infection. It appears that AgNPs
when present along with NABs were able to bind differ-
ent epitopes on gp120 and/or gp41 which NABs alone
did not bind and vice versa. The mechanism behind this
additive effect in cell-associated infection is not known
and needs further evaluation. Nevertheless, this is very
significant finding because cell- associated viruses are
the main source of HIV-1 transmission. Recently Diane
and colleagues have shown that latently infected CD4+
T cells in breast milk from women with or without anti-
retroviral drugs simultaneously produce HIV-1 and
increase chances of transmission between mothers to
infant [28]. A similar phenomenon is expected with
latently infected cells in semen and vaginal secretions.
In this light, the additive inhibitory efficiency of AgNPs
along with NABs against cell associated virus infection
is a very positive data that suggests use of this strategy
in developing antiviral vaginal gel/cream to prevent
HIV-1 virus transmission.
Conclusion
The NABs have been shown to inhibit HIV-1 transmis-
sion of infection at very high titers in vitro. But the
available vaccines under evaluation in various labs are
unable to elicit such high titers in vivo, resulting in low-
ered efficacy and/or failure of vaccine against viral chal-
lenges. Silver nanoparticles used along with NABs
against cell free HIV-1IIIB virus had no additive effect.
In the case of cell associated HIV-1IIIB/H9 virus, all four
NABs evaluated in this study showed almost no inhibi-
tory effect by itself. Only AgNPs showed capability to
inhibit cell- associated HIV-1IIIB/H9 virus. However,
when used together, the results showed additive effect,
increasing the inhibitory effect of AgNPs, and NABs
cocktail in case of all four NABs used. The mechanism
behind this increase in potency is not well understood
and requires further study.
Methods
Antibodies, cells and HIV-1 isolates
The HIV-1IIIB virus alongwith the following reagents
were obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID:
U373-MAGI-CXCR4CEM from Dr. Michael Emerman,
HTLV-IIIB from Dr. Robert Gallo, Monoclonal antibody
to HIV-1 gp41 (126-7) from Dr. Susan Zolla-Pazner,
HIV-1 gp120 Antiserum (PB1 Sub 2), HIV-1 gp120
Antiserum (PB1), and HIV-1 gp120 Monoclonal Anti-
body (F425 B4e8) from Dr. Marshall Posner and Dr.
Lisa Cavacini.
Silver compounds
Commercially manufactured 30-50 nm silver nanoparti-
cles, surface coated with 0.2 wt% PVP, were used
(Nanoamor, Houston, TX). Stock solutions were pre-
pared in RPMI 1640 cell culture media. The serial dilu-
tions of the stock were made in culture media.
Cytotoxicity Assay
A stock solution of AgNPS was two-fold diluted to
desired concentrations in growth medium and subse-
quently added into wells containing 5 × 104 U373-
MAGI-CXCR4CEM cells to a final volume of 100 μl.
Microtiter plates were incubated at 37°C in a 5% CO2
air humidified atmosphere for 24 hours. Assessments of
cell viability were carried out using a CellTiter-Glo®
Luminescent Cell Viability Assay and Glomax Multidir-
ection System (Promega). Cytotoxicity was evaluated
based on the percentage cell survival relative to the con-
trol in the absence of any compound [21].
Range of antiviral activity of Neutralizing Antibodies
(NABs) against HIVIIIB cell-free virus
Serial two-fold dilutions of neutralizing antibodies:
Monoclonal antibody to HIV-1 gp41 (126-7), HIV-1
gp120 Antiserum (PB1 Sub 2), HIV-1 gp120 Antiserum
(PB1), and HIV-1 gp120 Monoclonal Antibody (F425
B4e8) or just media as control were added to HIV-1IIIB
cell-free virus to a final volume of 50 μl. After incuba-
tion for 5 min at room temperature we added media
with or without AgNPs 1 mg/mL and placed into 96-
well plates with U373-MAGI-CXCR4CEM cells to a final
volume of 50 μl. The cells were incubated in a 5% CO2
humidified incubator at 37°C for 24 h. Assessment of
HIV-1 infection was performed with the Beta-Glo Assay
System using Glomax Multidirection System (Promega).
The percentage of residual infectivity after NABs or
media as control was calculated with respect to the con-
trol. The 50% inhibitory concentration (IC50) was
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defined according to the percentage of infectivity inhibi-
tion relative to the positive control.
Range of antiviral activity of Neutralizing Antibodies
(NABs) against HIVIIIB cell-associated virus
Serial two-fold dilutions of neutralizing antibodies:
Monoclonal antibody to HIV-1 gp41 (126-7), HIV-1
gp120 Antiserum (PB1 Sub 2), HIV-1 gp120 Antiserum
(PB1), and HIV-1 gp120 Monoclonal Antibody (F425
B4e8) or just media as control were added to H9 cells
(5 × 104 per well) chronically infected with HIVIIIB to a
final volume of 50 μl. After incubation for 5 min at
room temperature we added media with or without
AgNPs 1 mg/mL and placed into 96-well plates with
U373-MAGI-CXCR4CEM cells to a final volume of 50 μl.
The cells were incubated in a 5% CO2 humidified incu-
bator at 37°C for 24 h. Assessment of HIV-1 infection
was performed with the Beta-Glo Assay System. The
percentage of residual infectivity after NABs or media as
control was calculated with respect to the control. The
50% inhibitory concentration (IC50) was defined accord-
ing to the percentage of infectivity inhibition relative to
the positive control.
Statistical analysis
Graphs were done with SigmaPlot 10.0 software and the
values shown are means ± standard deviations from
three separate experiments, each of which was carried
out in duplicate. Cytotoxicity and inhibition assessment
graphs are linear regression curves done with SigmaPlot
10.0 software. Wilcoxon rank-sum (Wilcoxon-Mann-
Whitney test) test was performed to compare the two
groups of results (HIV-1 infectivity by AgNPs, and
AgNPs mixed with NABs.
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